Search Results

Life Molecular Imaging and Oryx Isotopes Industrial Company announce a Strategic Partnership for the Production and Distribution of Florbetaben (18F) in the Kingdom of Saudi Arabia and other countries in reach

Life Molecular Imaging and Oryx Isotopes Industrial Company have announced a strategic partnership for the production and distribution of Florbetaben in the Kingdom of Saudi Arabia and other reachable countries, aiming to enhance the supply of this tracer for Amyloid-PET imaging in the Middle East and North Africa region.

February 6, 2024

·

5 min read

ORYX Confirms ParvOryx Mode of Action in Tumor Explant Model

ORYX, a translational medicine company focused on oncolytic virotherapy and cancer vaccines, reported new results on the mode of action of oncolytic virus ParvOryx in human ovarian cancer explants.

November 11, 2019

·

4 min read

Drug Development

ORYX Announces Positive Phase I/IIa Data for Oncolytic Virus ParvOryx Demonstrating Safety, Anti-tumor Effects, Partial Responses and Prolonged Overall Survival in Metastatic, Inoperable Pancreatic Cancer

ORYX, a translational medicine company focused on oncolytic virotherapy and cancer vaccines, today published positive clinical trial results from a dose-escalating Phase I/IIa trial with oncolytic virus ParvOryx in metastatic, inoperable pancreatic cancer.

October 30, 2019

·

4 min read

Policy

ORYX Provides Strategic Update on the Clinical Development of Oncolytic Virotherapy ParvOryx

Endorsement of pivotal development program in recurrent glioblastoma (rGBM) from both EMA and FDA

November 4, 2019

·

4 min read

Drug Development

ORYX Reports Positive Clinical Evidence With Oncolytic Virus ParvOryx In Combination With Immuno-Oncology Drugs

May 23, 2017